tbuckley/cabot-search huggingface dataset:
Risk of Pulmonary Embolism More Than 6 Weeks After Surgery Among Cancer-Free Middle-aged Patients
Authors: Alexandre Caron, Nicolas Depas, Emmanuel Chazard, Cécile Yelnik, Emmanuelle Jeanpierre, Camille Paris, Jean-Baptiste Beuscart, Grégoire Ficheur
Journal: JAMA Surgery (2019)

<h3>Importance</h3> The risk of postoperative pulmonary embolism has been reported to be highest during the first 5 weeks after surgery. However, how long the excess risk of postoperative pulmonary embolism persists remains unknown. <h3>Objective</h3> To assess the duration and magnitude of the late postoperative risk of pulmonary embolism among cancer-free middle-aged patients by the type of surgery. <h3>Design, Setting, and Participants</h3> Case-crossover analysis to compute the respective risks of pulmonary embolism after 6 types of surgery using data from a French national inpatient database, which covers a total of 203 million inpatient stays over an 8-year period between 2007 and 2014. Participants were cancer-free middle-aged adult patients (aged 45 to 64) with a diagnosis of a first pulmonary embolism. <h3>Exposures</h3> Hospital admission for surgery. Surgical procedures were classified into 6 types: (1) vascular surgery, (2) gynecological surgery, (3) gastrointestinal surgery, (4) hip or knee replacement, (5) fractures, and (6) other orthopedic operations. <h3>Main Outcomes and Measures</h3> Diagnosis of a first pulmonary embolism. <h3>Results</h3> A total of 60 703 patients were included (35 766 [58.9%] male; mean [SD] age, 56.6 [6.0] years). The risk of postoperative pulmonary embolism was elevated for at least 12 weeks after all types of surgery and was highest during the immediate postoperative period (1 to 6 weeks). The excess risk of postoperative pulmonary embolism ranged from odds ratio (OR), 5.24 (95% CI, 3.91-7.01) for vascular surgery to OR, 8.34 (95% CI, 6.07-11.45) for surgery for fractures. The risk remained elevated from 7 to 12 weeks, with the OR ranging from 2.26 (95% CI, 1.81-2.82) for gastrointestinal operations to 4.23 (95% CI, 3.01-5.92) for surgery for fractures. The risk was not clinically significant beyond 18 weeks postsurgery for all types of procedures. <h3>Conclusions and Relevance</h3> The risk of postoperative pulmonary embolism is elevated beyond 6 weeks postsurgery regardless of the type of procedure. The persistence of this excess risk suggests that further randomized clinical trials are required to evaluate whether the duration of postoperative prophylactic anticoagulation should be extended and to define the optimal duration of treatment with regard to both the thrombotic and bleeding risks.
– Updated Results from the Bridge Trial: Long-Term Survival and Impact of Donor Availability – Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML
Authors: Jan Moritz Middeke, Regina Herbst, Stefani B Parmentier, Gesine Bug, Mathias Hänel, Gernot Stuhler, Kerstin Schäfer-Eckart, Wolf Rösler, Stefan A. Klein, Wolfgang Bethge, Ulrich Bitz, Nael Alakel, Markus Schaich, Anke Morgner, Michael Kramer, Uwe Platzbecker, Christoph Röllig, Christian Thiede, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig
Journal: Blood (2014)
Dissociation of In Vivo and in Vitro Differentiation Capacity of Human Mesenchymal Stem Cells Is Reflected by a Tissue Specific Epigenetic Memory
Authors: Andreas Reinisch, Nathalie Liechtenstein, Nicole A Hofmann, Anna Ortner, Margareta Frühwirth, Katharina Schallmoser, Christine Beham-Schmid, Dirk Strunk
Journal: Blood (2011)
Characterization of the Microrna Expression Profiles of Paired Primary and Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) By Next-Generation Sequencing
Authors: Suvi-Katri Leivonen, Katherine Icay, Chengyu Liu, Minna Taskinen, Rainer Lehtonen, Marja-Liisa Karjalainen-Lindsberg, Jan Delabie, Harald Holte, Sampsa Hautaniemi, Sirpa Leppä
Journal: Blood (2014)
The Case of Noninvasive Cardiac Testing—For Every Action There Is a Reaction
Authors: Jose F. Figueroa, Karen E. Joynt Maddox
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
The Clinical Phenotype of Patients with Essential Thrombocythemia Harboring MPL 515W&gt;L/K Mutation.
Authors: Alessandro M. Vannucchi, Elisabetta Antonioli, Alessandro Pancrazzi, Paola Guglielmelli, Simonetta Di Lollo, Renato Alterini, Vittoria Guerini, Gianna Baroni, Alessandro Rambaldi, Alberto Bosi, Tiziano Barbui
Journal: Blood (2007)
Optimizing Iron Chelation Therapy with Deferasirox for Non-Transfusion-Dependent Thalassemia Patients: 1-Year Results from the Phase IV, Open-Label Thetis Study
Authors: Ali T Taher, M Domenica Cappellini, Yesim Aydinok, John B. Porter, Zeynep Karakas, Vip Viprakasit, Noppadol Siritanaratkul, Antonis Kattamis, Candace Wang, Zewen Zhu, Victor Joaquin, Marie José Uwamahoro, Yong-Rong Lai
Journal: Blood (2015)
A Dominant Negative Mutation (p.P214L) in ETV6 is Associated with Megakaryocyte and Erythroid Transcript Misregulation
Authors: Leila Noetzli, Jesse W Rowley, Michael U Callaghan, Madhvi Rajpurkar, Alisa B. Lee-Sherick, Christopher C. Porter, Andrew S. Weyrich, Jorge A. Di Paola
Journal: Blood (2015)
Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence
Authors: Victoria L. Bartlett, Sanket S. Dhruva, Nilay D. Shah, Patrick Ryan, Joseph S. Ross
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Although randomized clinical trials are considered to be the criterion standard for generating clinical evidence, the use of real-world evidence to evaluate the efficacy and safety of medical interventions is gaining interest. Whether observational data can be used to address the same clinical questions being answered by traditional clinical trials is still unclear. <h3>Objective</h3> To identify the number of clinical trials published in high-impact journals in 2017 that could be feasibly replicated using observational data from insurance claims and/or electronic health records (EHRs). <h3>Design, Setting, and Participants</h3> In this cross-sectional analysis, PubMed was searched to identify all US-based clinical trials, regardless of randomization, published between January 1, 2017, and December 31, 2017, in the top 7 highest-impact general medical journals of 2017. Trials were excluded if they did not involve human participants, did not use end points that represented clinical outcomes among patients, were not characterized as clinical trials, and had no recruitment sites in the United States. <h3>Main Outcomes and Measures</h3> The primary outcomes were the number and percentage of trials for which the intervention, indication, trial inclusion and exclusion criteria, and primary end points could be ascertained from insurance claims and/or EHR data. <h3>Results</h3> Of the 220 US-based trials analyzed, 33 (15.0%) could be replicated using observational data because their intervention, indication, inclusion and exclusion criteria, and primary end points could be routinely ascertained from insurance claims and/or EHR data. Of the 220 trials, 86 (39.1%) had an intervention that could be ascertained from insurance claims and/or EHR data. Among the 86 trials, 62 (72.1%) had an indication that could be ascertained. Forty-five (72.6%) of 62 trials had at least 80% of inclusion and exclusion criteria data that could be ascertained. Of these 45 studies, 33 (73.3%) had at least 1 primary end point that could be ascertained. <h3>Conclusions and Relevance</h3> This study found that only 15% of the US-based clinical trials published in high-impact journals in 2017 could be feasibly replicated through analysis of administrative claims or EHR data. This finding suggests the potential for real-world evidence to complement clinical trials, both by examining the concordance between randomized experiments and observational studies and by comparing the generalizability of the trial population with the real-world population of interest.
Novel Activating STAT5B Mutations As Drivers Of T-ALL
Authors: Mika Kontro, Heikki Kuusanmäki, Samuli Eldfors, Tea Pemovska, Hanna L M Rajala, Henrik Edgren, Pekka Ellonen, Sonja Lagström, Tuija Lundán, Olli Kallioniemi, Satu Mustjoki, Kimmo Porkka, Caroline Heckman
Journal: Blood (2013)
Hematopoietic Stem and Progenitor Cells from Human Pluripotent Stem Cells Via Transcription Factor Conversion of Hemogenic Endothelium
Authors: Ryohichi Sugimura, Areum Han, Deepak Jha, Yi-Fen Lu, Jeremy A Goettel, Erik Serrao, Robert Grant Rowe, Irene Wong, Patricia Sousa, Andrea Ditadi, Gordon Keller, Alan Engelman, Scott Snapper, Sergei Doulatov, George Q. Daley
Journal: Blood (2016)
Correlation of Cytomorphology, Immunophenotyping, and Interphase Fluorescence in Situ Hybridization (FISH) in 381 Patients with MGUS and 310 Patients with Multiple Myeloma.
Authors: Ulrike Bacher, Torsten Haferlach, Wolfgang Kern, Tamara Weiss, Susanne Schnittger, Claudia Haferlach
Journal: Blood (2009)
What Are the Most Important Symptoms and Concerns of Patients with Indolent Non-Hodgkin's Lymphoma? Content Validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18)
Authors: Karen Kaiser, Sara Shaunfield, Kimberly Webster, Karen Keating, Lara Boyken, Sara Duffey, Jessica Yarber, David Cella
Journal: Blood (2016)
A single institute analysis of cell-free DNA concentrations in plasma of patients with various cancer types
Authors: Takuro Noguchi, Mariko Miyagawa, Nodoka Sekiguchi, Daisuke Gomi, Toshiro Fukushima, Takesumi Ozawa, Takashi Kobayashi, Shun’ichiro Taniguchi, Tomonobu Koizumi
Journal: Annals of Oncology (2019)
Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1st Line IM Patients.
Authors: Jaspal Kaeda, Andreas Hochhaus, Jerald Radich, Susan Branford, Charlene So, Insa Gathmann, Elisabeth Wehrle, John Goldman, Timothy Hughes
Journal: Blood (2006)
Characterization of Metabolic Response to AG-348, an Allosteric Activator of Red Cell Pyruvate Kinase, in Healthy Volunteers and Pyruvate Kinase Deficiency Patients
Authors: Victor Chubukov, Kendall Johnson, Penelope A Kosinski, Michelle Clasquin, Abhishek Jha, Hyeryun Kim, Thomas P Roddy, Elizabeth Merica, Ann J Barbier, Lenny Dang, Lee Silverman, Charles Kung
Journal: Blood (2016)
Identification of Novel Fusion Genes with 28S Ribosomal DNA in Hematologic Malignancies
Authors: Satoru Kobayashi, Tomohiko Taki, Hisao Nagoshi, Yoshiaki Chinen, Yuichi Yokokawa, Hirokazu Kanegane, Yosuke Matsumoto, Junya Kuroda, Shigeo Horiike, Kazuhiro Nishida, Masafumi Taniwaki
Journal: Blood (2012)
Estimating the ‘PrEP Gap’: how implementation and access to PrEP differ between countries in Europe and Central Asia in 2019
Authors: Rosalie Hayes, Axel J Schmidt, Anastasia Pharris, Yusef Azad, Alison E Brown, Peter Weatherburn, Ford Hickson, Valerie Delpech, Teymur Noori
Journal: Eurosurveillance (2019)

In 2019, only 14 European and Central Asian countries provided reimbursed HIV pre-exposure prophylaxis (PrEP). Using EMIS-2017 data, we present the difference between self-reported use and expressed need for PrEP in individual countries and the European Union (EU). We estimate that 500,000 men who have sex with men in the EU cannot access PrEP, although they would be very likely to use it. PrEP's potential to eliminate HIV is currently unrealised by national healthcare systems.
Hematopoietic Cell Differentiation from Common Marmoset (Callithrix jacchus) Embryonic Stem Cells by Their Genetic Manipulation Using the Third Generation Lentiviral Vector.
Authors: Ryo Kurita, Erika Sasaki, Takashi Hiroyama, Tomoko Yokoo, Yukoh Nakazaki, Kiyoko Izawa, Hajime Ishii, Yoshikuni Tanioka, Kisaburo Hanazawa, Takao Hashiguchi, Yuan-Son Bai, Yasushi Soda, Sumiko Watanabe, Shigetaka Asano, Kenzaburo Tani
Journal: Blood (2004)
Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial
Authors: Francois Guilhot, Hagop Kantarjian, Neil P. Shah, Andreas Hochhaus, M. Brigid Bradley-Garelik, David Dejardin, Jorge E. Cortes
Journal: Blood (2010)
Serial Gene Expression Studies of Malignant Plasma Cells before Treatment and after Relapse: Identifying Genes Linked to Drug Resistance in Myeloma.
Authors: Fenghuang Zhan, Sisi Kapp, Y. Huang, Elias J. Anassie, H. Xu, I. Hanamura, Jeffrey Sawyer, M. Santra4, Choon-Kee Lee, Athanasios Fassas, Frits van Rhee, Klaus Hollmig, Giampaulo Talamo, Raymond Thertulien, Guido Tricot, William Barlow, Erik Rasmussen, John Crowley, Bart Barlogie, John Shaughnessy
Journal: Blood (2004)
Efficacy of Low Dose Clofarabine Plus Intermediate Dose Cytarabine In An Unselected AML Refractory/Relapsed Adult Population
Authors: Claudio Romani, Emanuele Angelucci, Barbara Scappini, Mario Petrini, Martina Pettinau, Filippo Marmont, Francesco Caracciolo, Ernesta Audiosio, Alberto Bosi
Journal: Blood (2010)
MSI2 and HOXA9 Expression Is Significantly Increased in Patients with Primary Myelofibrosis
Authors: Jaspal S Kaeda, Jackline Ayres-Silva, Leila Amini, Iris von Wunsch-Rolshoven, Frauke Ringel, Michaela Schwarz, Bernd Dörken, Ilana Zalcberg, Philipp le Coutre
Journal: Blood (2014)
Clinical Activity and Safety of RP6530, a Dual PI3Kδ/γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study
Authors: Carmelo Carlo-Stella, Richard Delarue, Prajak J Barde, Lydia Scarfo, Uday Kumar, Srikant Viswanadha, Silvia Laura Locatelli, Sara Gandolfi, Valeria Pittari, Lucia Morello, Massimo Magagnoli, Armando Santoro, Andrés J.M. Ferreri
Journal: Blood (2016)
Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning. a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT
Authors: Avichai Shimoni, Arnon Nagler, Simona Iacobelli, Anja van Biezen, Dietrich Beelen, Ghulam J. Mufti, Fabio Ciceri, Lothar Kanz, Liisa Volin, Carlos Richard, Didier Blaise, Arnold Ganser, Thomas Luft, Patrice Chevallier, Rainer Schwerdtfeger, Theo de Witte, Marie Robin, Nicolaus Kröger
Journal: Blood (2014)
Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML).
Authors: Kiran Naqvi, Farhad Ravandi, Hagop Kantarjian, Gautam Borthakur, Alessandra Ferrajoli, Deborah A Thomas, Charles Asa Koller, Marina Konopleva, Anna Byrd, Monica Kwari, Stefan Faderl
Journal: Blood (2010)
Wiskott-Aldrich Protein Is Phosphorylated by NPM-ALK and Regulates the Proliferation and Invasion of Anaplastic Large Cell Lymphoma
Authors: Carlos Murga-Zamalloa, Steven R Hwang, Anagh A Sahasrabuddhe, Scott RP McDonnell, Venkatesha Basrur, Zaneta Nikolovska-Coleska, Kojo S.J. Elenitoba-Johnson, Megan S. Lim
Journal: Blood (2012)
Inactivating Heat Shock Factor 1 (HSF1) in Acute Myeloid Leukemia By Pharmacological Inhibition of eIF4a: A Promising Therapeutic Approach
Authors: Jo Ishizawa, Rodrigo Omar Jacamo, Kensuke Kojima, Dhruv Chachad, Vivian Ruvolo, Peter Ruvolo, Weiguo Zang, Yoko Tabe, Marina Konopleva, William Devine, Susan Lindquist, John A Porco, Luke Whitesell, Michael Andreeff
Journal: Blood (2015)
The Correlation of APOBEC Gene Family Member Expression with Worse CLL Patient Outcome Suggests a Role in CLL Mutational Evolution
Authors: Charles C Chu, Xiao-Jie Yan, Arvind Dhayalan, Piers E. Patten, Thomas MacCarthy, Chaohui Yuan, Jacqueline C. Barrientos, Jonathan E. Kolitz, Steven L Allen, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2015)
The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma.
Authors: Christian Jakob, Peter Liebisch, Karl Egerer, Jan Sterz, Martin Kaiser, Susanne Rötzer, Ulrike Heider, Jessica Rademacher, Claudia Fleissner, Peter M. Kloetzel, Evangelos Terpos, Orhan Sezer
Journal: Blood (2007)
Downregulating Notch Counteracts KrasG12D-Induced ERK Activation and Oxidative Phosphorylation in Myeloproliferative Neoplasm
Authors: Guangyao Kong, Yuan-I Chang, Jingfang Zhang, Erik A. Ranheim, Xinmin Zhang, Yun Zhou, Yangang Liu, Lan Zhou, Warren S. Pear, Jing Zhang
Journal: Blood (2016)
Malignant Reprogramming of Progenitors into Leukemia Stem Cells Is Enhanced By Upregulation of CD44 Transcript Variant 3 in Malignant Microenvironments
Authors: Frida L Holm, Eva Hellqvist, Cayla N Mason, Christian L Barrett, Shawn Ali, Hye-Jung Chun, Marco A. Marra, Valeria Runza, Kelly A Frazer, Anil Sadarangani, Catriona Jamieson
Journal: Blood (2014)
The JAK2-V617 Mutation Status Identifies Subtypes of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis.
Authors: Annette Schmitt-Graeff, Soon-Siong Teo, Manfred Olschewski, Andreas Kirn, Petra Reinecke, Ulrich Germing, Radek C. Skoda
Journal: Blood (2006)
Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP
Authors: Nathalie A Johnson, Joseph M. Connors, Susana Ben-Neriah, Sanja Rogic, Kerry Joanne Savage, Christian Steidl, Douglas E Horsman, Graham W. Slack, Laurie Sehn, Wing-Chung Chan, Javeed Iqbal, Paul N. Meyer, Georg Lenz, George W Wright, Lisa M. Rimsza, Carlo Valentino, Patrick Brunhoeber, Thomas Grogan, Rita M. Braziel, James Cook, Raymond R. Tubbs, Dennis D. Weisenburger, Elias Campo, Andreas Rosenwald, German Ott, Jan Delabie, Elaine Jaffe, Louis M. Staudt, Randy D. Gascoyne
Journal: Blood (2010)
Detection of High Molecular Weight Light Chain Oligomers in Urinary Exosomes of Patients with AL Amyloidosis.
Authors: Marina Ramirez-Alvarado, Christopher J Ward, Bing Q Huang, Xun Gong, Marie C Hogan, Benjamin J Madden, Cristine Charlesworth, Angela Dispenzieri, Morie A Gertz, Nelson Leung
Journal: Blood (2009)
KIRs Expression and Cytotoxic Activities of Cord Blood Natural Killer Cells Against Acute Lymphoblastic Leukemia with MLL Gene Rearrangement.
Authors: Hiroko Honna, Kumiko Goi, Kinuko Hirose, Itaru Kuroda, Takeshi Inukai, Keiko Kagami, Kanji Sugita
Journal: Blood (2007)
Diversification of host bile acids by members of the gut microbiota
Authors: Jenessa A. Winston, Casey M. Theriot
Journal: Gut Microbes (2019)

Bile acid biotransformation is a collaborative effort by the host and the gut microbiome. Host hepatocytes synthesize primary bile acids from cholesterol. Once these host-derived primary bile acids enter the gastrointestinal tract, the gut microbiota chemically modify them into secondary bile acids. Interest into the gut-bile acid-host axis is expanding in diverse fields including gastroenterology, endocrinology, oncology, and infectious disease. This review aims to 1) describe the physiologic aspects of collaborative bile acid metabolism by the host and gut microbiota; 2) to evaluate how gut microbes influence bile acid pools, and in turn how bile acid pools modulate the gut microbial community structure; 3) to compare species differences in bile acid pools; and lastly, 4) discuss the effects of ursodeoxycholic acid (UDCA) administration, a common therapeutic bile acid, on the gut microbiota-bile acid-host axis.
Treatment of Splenic Marginal Zone Lymphoma with Rituximab Monotherapy in 59 Patients
Authors: Christina H. Kalpadakis, Gerassimos Pangalis, Theodoros P. Vassilakopoulos, Sotirios P. Sachanas, Flora Kontopidou, Xanthi Yiakoumis, Styliani Kokoris, Evangelia Dimitriadou, Maria Dimopoulou, Maria Moschogiannis, Penelope Korkolopoulou, Marie-Christine Kyrtsonis, Marina Siakantaris, Helen A. Papadaki, Maria K. Angelopoulou
Journal: Blood (2011)
T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol
Authors: P. Quist-Paulsen, N. Toft, M. Heyman, J. Abrahamsson, L. Griškevičius, H. Hallböök, Ó. G. Jónsson, K. Palk, G. Vaitkeviciene, K. Vettenranta, A. Åsberg, T. L. Frandsen, S. Opdahl, H. V. Marquart, S. Siitonen, L. T. Osnes, M. Hultdin, U. M. Overgaard, U. Wartiovaara-Kautto, K. Schmiegelow
Journal: Leukemia (2019)
Pro-Coagulant and Pro-Inflammatory Effect of Interferon Alpha in Myeloproliferative Neoplasms
Authors: Nadine Ajzenberg, Dorothee Faille, Lamia Lamrani, Stéphane Loyau, Marie-Geneviève Huisse, Nicolas Dumontier, Martine Jandrot-Perrus, Sawsaneh Alkhaier, Bruno Cassinat, Christine Chomienne, Christine Dosquet
Journal: Blood (2016)
Targeting Oncogenic Interleukein-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia
Authors: Marc R. Mansour, Casie Reed, Amy Eisenberg, Jen-Chieh Tseng, Akinori Yoda, Scott J Rodig, Daniel J. DeAngelo, Stephen E. Sallan, David M. Weinstock, Shai Izraeli, Andrew L Kung, Alex Kentsis, Thomas Look
Journal: Blood (2013)
Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT)
Authors: Mohamed L. Sorror, Rainer Storb, Paul J Martin, Smita Bhatia, Richard T. Maziarz, Michael A. Pulsipher, Michael T. Maris, H. Joachim Deeg, Frederick R. Appelbaum, David G. Maloney, Brenda M. Sandmaier, Ted A. Gooley
Journal: Blood (2011)
Autophagy Defects in Skeletal Myopathies
Authors: Marta Margeta
Journal: Annual Review of Pathology Mechanisms of Disease (2019)

Autophagy is an evolutionarily conserved catabolic process that targets different types of cytoplasmic cargo (such as bulk cytoplasm, damaged cellular organelles, and misfolded protein aggregates) for lysosomal degradation. Autophagy is activated in response to biological stress and also plays a critical role in the maintenance of normal cellular homeostasis; the latter function is particularly important for the integrity of postmitotic, metabolically active tissues, such as skeletal muscle. Through impairment of muscle homeostasis, autophagy dysfunction contributes to the pathogenesis of many different skeletal myopathies; the observed autophagy defects differ from disease to disease but have been shown to involve all steps of the autophagic cascade (from induction to lysosomal cargo degradation) and to impair both bulk and selective autophagy. To highlight the molecular and cellular mechanisms that are shared among different myopathies with deficient autophagy, these disorders are discussed based on the nature of the underlying autophagic defect rather than etiology or clinical presentation.
Phase I Study to Improve Virus-Specific Immune Reconstitution After Cord Blood Transplantation Using Cord Blood-Derived Virus-Specific Cytotoxic T Lymphocytes
Authors: Patrick J Hanley, Caridad Martinez, Kathryn Leung, Barbara Savaldo, Gianpietro Dotti, Adrian P. Gee, Cliona M. Rooney, Helen E. Heslop, Robert A. Krance, Elizabeth J Shpall, Catherine M. Bollard
Journal: Blood (2011)